IMVT Immunovant Inc

Price (delayed)

$32.7

Market cap

$6.71B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.77

Enterprise value

$5.81B

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous ...

Highlights
Immunovant's debt has decreased by 27% YoY
The equity has grown by 21% YoY but it has contracted by 14% from the previous quarter
IMVT's quick ratio is down by 42% since the previous quarter and by 17% year-on-year
IMVT's net income is down by 22% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of IMVT

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
4.98%
1 week
-2.39%
1 month
17.41%
1 year
113.17%
YTD
28.64%
QTD
31.64%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$532.9M
Net income
-$505.61M
Gross margin
N/A
Net margin
N/A
IMVT's net income is down by 22% YoY and by 9% from the previous quarter
The operating income has declined by 22% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does IMVT's price correlate with its fundamentals

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
7.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 3.4% QoQ
The stock's price to book (P/B) is 46% more than its last 4 quarters average of 5.1 and 26% more than its 5-year quarterly average of 5.9
The equity has grown by 21% YoY but it has contracted by 14% from the previous quarter

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity is up by 15% year-on-year but it is down by 3.6% since the previous quarter
IMVT's return on assets is up by 13% year-on-year but it is down by 3% since the previous quarter

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's total liabilities has surged by 58% since the previous quarter and by 52% year-on-year
Immunovant's current ratio has decreased by 42% QoQ and by 19% YoY
Immunovant's debt is 100% lower than its equity
Immunovant's debt has decreased by 27% YoY
The equity has grown by 21% YoY but it has contracted by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.